Lightnews — Scholar-powered news

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · 1d

FDA approves Novo Nordisk’s Rybelsus (oral semaglutide) to cut major heart risks in adults with type 2 diabetes. The SOUL trial showed a 14% reduction in cardiovascular events.

jcst2d.com/index.php/ne...

#Type2Diabetes #Rybelsus #HeartHealth #NovoNordisk

Oral semaglutide (Rybelsus). Courtesy of Novo Nordisk.

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · 4d

Lilly’s oral GLP-1 orforglipron outshines Farxiga in Type 2 diabetes—a1C, weight, and heart metrics all improved.

jcst2d.com/index.php/ne...

#orforglipron #Farxiga #Type2Diabetes

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · 21d

Novo Nordisk has resubmitted Awiqli® (insulin icodec) to the FDA for type 2 diabetes, offering fewer injections and a simpler treatment routine.

jcst2d.com/index.php/ne...

#NovoNordisk #Awiqli #Type2Diabetes #Insulin #DiabetesResearch

Awiqli® (insulin icodec) pen. Courtesy of Novo Nordisk Canada.

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · 28d

Dexcom introduced Smart Basal at EASD 2025, a G7 app feature under FDA and CE Mark review that simplifies basal insulin initiation and adjustment.

jcst2d.com/index.php/ne...

#Dexcom #SmartBasal #EASD2025 #DiabetesCare #CGM

Illustration from the Dexcom G7 app showing the Dexcom Smart Basal feature. A hand holds a smartphone with a glucose trend line on the screen, next to a vial of insulin highlighted in a green circle. Text explains that glucose data is used to recommend a daily long-acting insulin dose.

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Sep 21

Novo Nordisk’s INFORM survey shows people on Wegovy® had 46% less “food noise,” plus boosts in mental health, habits & lifestyle. Sample size (550, mostly women, avg age 53) may limit generalizability.

jcst2d.com/index.php/ne...

#Wegovy #ObesityCare #PatientExperience

Novo Nordisk Flags. Courtesy of Novo Nordisk.

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Sep 21

Lilly’s oral GLP-1, orforglipron, delivers strong Phase 3 results with significant weight loss in obesity, superior A1C and weight outcomes vs oral semaglutide in type 2 diabetes.

jcst2d.com/index.php/ne...

#Orforglipron #ObesityTreatment #Type2Diabetes #WeightLoss

1

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Sep 14

CGMs, wearables, biobanks, and registries show how personalized medicine in the Nordics connects to diabetes care and more broadly to medical care more broadly.

jcst2d.com/index.php/ar...

#Diabetes #CGM #HealthcareData #PersonalisedMedicine

Certificate of completion from Coursera for the course ‘Personalised Medicine from a Nordic Perspective,’ authorized by the University of Copenhagen and the University of Iceland, awarded to Jeffrey Smith on September 12, 2025.

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Sep 8

Novonesis and Novo Nordisk team up to explore how gut-targeted synbiotics might support metabolic health and tackle obesity and related conditions.

jcst2d.com/index.php/ne...

#Novonesis #NovoNordisk #GutMicrobiome #MetabolicHealth #ObesityPrevention

Logos of Novo Nordisk and Novonesis displayed over a blue-toned background of magnified gut microbiome imagery. Courtesy of Novonesis.

2

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Sep 7

CVS Caremark faces a class-action lawsuit over dropping Zepbound in favor of Wegovy. Plaintiffs cite differences in indications, patient tolerability, and outcomes; experts point out why the two drugs may be complementary.

jcst2d.com/index.php/ne...

#CVSCaremark #Wegovy #Zepbound #GLP1 #HealthLaw

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Sep 4

Lilly ends two phase 2 trials of oral GLP-1 naperiglipron in type 2 diabetes and healthy adults. A study in obesity continues into 2026. The move reflects the market’s obesity focus, but the drug’s future remains uncertain.

jcst2d.com/index.php/ne...

#GLP1 #Obesity #DiabetesCare #ClinicalTrials

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Aug 31

Novo Nordisk’s Wegovy cut the risk of heart attack, stroke or death by 57% compared to tirzepatide in a real-world study of people with obesity and cardiovascular disease.

jcst2d.com/index.php/ne...

#Wegovy #Mounjaro #Cardiovascular #Obesity #Diabetes

Wegovy 0.25 mg semaglutide injection pen for subcutaneous use, white body with teal and white label and gray cap.

2

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Aug 29

Teva's generic Saxenda (liraglutide) wins FDA approval, after its Victoza generic in 2024. Obesity drug market could nearly triple by 2030 with access, affordability & generics driving growth.

jcst2d.com/index.php/ne...

#Teva #GenericSaxenda #ObesityTreatment #FDAApproval #AccessToMedications

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Aug 29

Novo Nordisk inks a $550M deal with Replicate Bioscience to develop self-replicating RNA (srRNA) therapies for obesity and type 2 diabetes. Durable effects at lower doses spark optimism.

jcst2d.com/index.php?vi...

#srRNA #NovoNordisk #ReplicateBioscience #Obesity #Diabetes

1

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Aug 27

FDA expands Repatha access for adults with uncontrolled LDL-C at high cardiovascular risk—even without prior heart disease. For people with diabetes, this opens a new and effective treatment path.

jcst2d.com/index.php?vi...

#Repatha #Cholesterol #Diabetes #CardiovascularHealth #LDL

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Aug 26

Eli Lilly’s oral GLP-1 orforglipron posts successful Phase 3 results with 10.5 % weight loss and A1C reduction in obese and T2D patients. Analysts note its small-molecule cost edge over Novo’s semaglutide.

jcst2d.com/index.php?vi...

#orforglipron #Lilly #oralGLP1 #Phase3 #T2D

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Aug 21

Signos announced FDA clearance for weight management, but records show only glucose monitoring was cleared, not weight loss claims. Learn what was actually approved.

jcst2d.com/index.php?vi...

#FDA #Signos #CGM #DiabetesTech

Yellow caution triangle with a white exclamation mark in the center.

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Aug 18

Novo Nordisk expands its $499 cash-pay option to Ozempic, offering U.S. patients with type 2 diabetes a lower-cost alternative and increasing pressure on rival Eli Lilly.

jcst2d.com/index.php?vi...

#Ozempic #Type2Diabetes #NovoNordisk #Semaglutide

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Aug 16

FDA grants accelerated approval for Wegovy (semaglutide) to treat adults with MASH and liver fibrosis, expanding its role beyond obesity and cardiovascular care.

jcst2d.com/index.php?vi...

#FDA #Wegovy #MASH #Semaglutide

Box of Wegovy (semaglutide) injection 2.4 mg/0.75 mL with a prefilled pen displayed in front, alongside five additional single-dose prefilled pens shown to the right. Packaging indicates once-weekly subcutaneous use.

1

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Aug 13

Compare CGM and BGM readings using a 15-minute pairing window to evaluate sensor accuracy, placement, and performance, helping guide confident glucose decisions.

jcst2d.com/index.php/ar...

#CGM #BGM #DiabetesData #GlucoseMonitoring

Bar chart showing average percent difference between BGM and CGM readings by day and time of day, grouped into AM and PM values. Green bars indicate alignment quality: darker green for “Excellent” (0–10%), lighter green for “Good” (11–20%). Most values fall within the Excellent range, with a few in the Good range—such as 8.5% on Monday PM and 16.0% on Wednesday PM. A summary on the right shows week and combined averages, and a key explains the range categories based on absolute percent difference.

1

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Aug 13

Researchers found blood-based epigenetic markers that may predict heart disease risk in type 2 diabetes, potentially leading to personalized prevention and care.

jcst2d.com/index.php/ar...

#Type2Diabetes #HeartHealth #PrecisionMedicine

Professor Charlotte Ling. Courtesy of Lund University Diabetes Centre LUDC. Photograph by Kennet Ruona.

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Aug 9

New research finds gut-derived proteins RORDEP1/2 may enhance GLP-1 effects—boosting insulin, fat burning, and weight control. Early trials are underway.

jcst2d.com/index.php/ar...

#Diabetes #Obesity #GutMicrobiome #GLP1 #MetabolicHealth

Infographic titled 'Potential Synergy of RORDEPs and GLP-1 Drugs' showing digestive system organs, liver, fat tissue, and a gut bacterium labeled Ruminococcus. Arrows illustrate how RORDEPs and GLP-1 drugs increase incretin hormones (GLP-1, PYY), reduce glucose production, boost fat burning, and lower appetite.

1

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Aug 7

Lilly’s orforglipron shows 12.4% weight loss in Phase 3, falling short of expectations. Novo’s oral semaglutide 25 mg may gain early advantage.

jcst2d.com/index.php?vi...

#ObesityTreatment #GLP1 #EliLilly #NovoNordisk #WeightLoss

1

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Aug 1

Yes. That suggests the results are good compared to dulaglutide, but not significantly different.

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Jul 31

Lilly’s Mounjaro shows heart health benefits in a major trial of adults with type 2 diabetes. The findings support its broader use beyond glucose control.

jcst2d.com/index.php?vi...

#Mounjaro #Tirzepatide #Type2Diabetes #CardiovascularHealth #GLP1

A close-up image of a Mounjaro (tirzepatide) injection pen, labeled with the dosage 15 mg/0.5 mL.

1

JCS/T2D - A Diabetes Journey @jcst2d.bsky.social · Jul 30

Novo Nordisk lowers 2025 outlook, names Mike Doustdar CEO, and restructures R&D under Martin Holst Lange to focus on diabetes and obesity innovation.

jcst2d.com/index.php?vi...

#NovoNordisk #Wegovy #Ozempic #ObesityCare #DiabetesCare

Maziar Mike Doustdar, newly appointed CEO of Novo Nordisk, standing in front of a glass wall with his reflection visible. Courtesy of Novo Nordisk.

1